GLP-1 Medications for Weight Loss: From Skepticism to Evidence-Based Confidence

GLP-1s (“I Was Hesitant Too”)

When GLP-1 medications first started dominating headlines, I was cautious.

Weight loss has never lacked for promises, and as a physician, I’m slow to embrace anything that sounds like a shortcut. For years, my approach centered on structured nutrition, metabolic testing, and carefully designed exercise programs. And those methods absolutely work—if they’re sustainable.

But many people spend decades losing and regaining the same 10 or 20 pounds. At some point, the question becomes less about willpower and more about biology.

If excess weight contributes to elevated blood pressure, cholesterol, insulin resistance, joint pain, and cardiovascular risk—and we now have medications like semaglutide and other GLP-1 receptor agonists that meaningfully shift that biology—they deserve a serious, evidence-based look.

The data are difficult to ignore.

In the SELECT trial, which followed more than 17,000 patients with obesity and established cardiovascular disease, semaglutide reduced the risk of heart attack, stroke, and cardiovascular death by 20%. That’s not cosmetic weight loss—that’s meaningful cardiovascular risk reduction.

GLP-1 medications also lower blood pressure, reduce visceral fat (the inflammatory fat surrounding our organs), improve blood sugar regulation, and decrease overall metabolic strain.

Body composition matters too. Earlier GLP-1 therapies produced weight loss that was approximately 60% fat and 40% lean tissue. Newer medications that act on multiple appetite and metabolic pathways are showing closer to 75–80% fat loss—even in individuals who are not exercising intensively. When combined with resistance training and adequate protein intake, muscle loss becomes something we can actively manage rather than passively accept.

Are there side effects? Of course.

The most common include nausea, constipation, early satiety, and dehydration—effects that are directly tied to how these medications work. Like any medical therapy, GLP-1 medications are not appropriate for everyone, and decisions should always be made in partnership with a physician.

Do patients need to stay on these medications long-term?

Not necessarily. However, weight regulation is influenced by a biological “set point,” and discontinuing therapy too quickly often leads to weight regain. Duration of treatment should be intentional, individualized, and aligned with long-term health goals.

After carefully reviewing the data—and more importantly, observing patient outcomes over time—I became comfortable recommending GLP-1 medications not casually, but confidently.

Skepticism is healthy.
So is allowing strong evidence to change your mind.

References

https://pubmed.ncbi.nlm.nih.gov/37952131/
https://pubmed.ncbi.nlm.nih.gov/33567185/
https://pubmed.ncbi.nlm.nih.gov/39996356/